We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Allos Therapeutics Sues Dr. Reddy’s Over Proposed Folotyn Generic

Allos Therapeutics Sues Dr. Reddy’s Over Proposed Folotyn Generic

July 17, 2014

Colorado-based Allos Therapeutics and three research organizations are suing Dr. Reddy’s over its proposed generic version of the brand manufacturer’s orphan lymphoma drug Folotyn.

The four plaintiffs allege that Dr. Reddy’s Paragraph IV ANDA on Folotyn (pralatrexate) would infringe the drug’s ’071, ’470 and ’078 patents, according to the complaint filed July 7 in U.S. District Court for the District of New Jersey. The plaintiffs received notice of the Indian generics maker’s ANDA May 27, according to the complaint.

Allos holds the NDA on Folotyn. Non-profit corporations Sloan-Kettering Institute for Cancer Research, Southern Research Institute and SRI International own the drug’s patents, which they’ve licensed exclusively to Allos, the complaint said.  

Folotyn was approved by the FDA in 2009 as the first drug to treat patients with relapsed or refractory peripheral T-cell lymphoma, a rare condition that the FDA estimates occurs in less than 9,500 patients in the U.S. each year.

Because of the rarity of the condition, the FDA granted the product orphan drug status to incentivize development of products that might not be financially viable otherwise. Orphan status gave Folotyn exclusive marketing for seven years, expiring September 2016.

The drug’s patents, however, last longer; both the ’470 and ’078 extend until 2025. Allos and the other plaintiffs want Dr. Reddy’s barred from any Folotyn generic at least until the patents expire, they said in their filing.

Dr. Reddy’s did not respond to a request for comment by press time. — Bryan Koenig

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Commercial Operations

Upcoming Events

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

  • 10Aug

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

  • FDA Warns Baby Neck Floats Used in Water Therapy Can Cause Death or Injury

  • U.S. Government Inks $3.2 Billion Contract With Pfizer-BioNTech for Vaccine Booster Campaign

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing